Gil Schwartzberg's Net Worth by Dr Clemen Chiang
Top Holdings That Increased Gil Schwartzberg's Net Worth Over Years

Top Holdings That Increased Gil Schwartzberg's Net Worth Over Years

Get details on Gil Schwartzberg's Top Holdings and Gil Schwartzberg Net Worth in the below article. Also, explore his trading performance.

Dr. Clemen Chiang
Dr. Clemen Chiang

Gil Schwartzberg, a director at Lixte Biotechnology Holdings, Inc., is thought to have a present net worth of around $203.82K. Approximately 281,108 shares of common shares in Lixte Biotechnology Holdings, Inc. are owned by Gil Schwartzberg. Gil Schwartzberg has sold products at Lixte Biotechnology Holdings, Inc. for an estimated total of $0 over the last four years.

What was the history of Gil Schwartzberg's insider trading?

On December 8, 2020, Gil Schwartzberg placed his highest buy order for 105,264 units, totaling more over $500,000. Over the course of their tenure at Lixte Biotechnology Holdings, Inc. for 4 years, Gil Schwartzberg has completed around 4 deals. Typically, Gil Schwartzberg trades in the months of December, April, January, and July, with 2021 being the busiest.

Performance of Gil Schwartzberg in Trading

Spiking keeps track of the stock performance following each of Gil Schwartzberg's purchases throughout various time periods. To be specific, Gil Schwartzberg purchased equities that, after three months, had an average return of 29.66%. Gil Schwartzberg's trading results are contrasted with market benchmark return over the same time frame in Spiking. When compared to the performance of the S&P 500 during the same time period, the success of the equities that Gil Schwartzberg purchased within three months outperformed it twice out of every two transactions.

Insider Trading At Skechers USA

Insiders at Skechers U.S.A. have sold approximately $475,659,391 worth of shares and purchased 608,000 units totaling $14,942,430 during the past 19 years. Robertgreenberg M Susangree, Michael Greenberg, and Jeffrey Greenberg are some of the most engaged insiders traders. Executives and independent directors of Skechers U.S.A. trade shares on average once every 30 days for a value of $2,282,700. On December 7, 2022, Phillip Paccione made the most recent stock transaction, exchanging 561 shares of SKX stock valued $24,084 at the time.

About Sketchers

Skechers is a footwear, apparel, and accessory company with headquarters in Manhattan Beach, California. It creates a wide range of lifestyle and performance shoes, clothes, and accessories for people of all ages. The Company's products are offered through departmental and specialty shops, as well as 3,770 Company- and third-party-owned retail locations and e-commerce websites that sell directly to customers across the United States and more than 170 other countries and territories. Through a network of foreign distributors, joint venture partners in Asia, Israel, and Mexico, as well as wholly-owned companies in Canada, Japan, India, Europe, and Latin America, the company operates its global business.

Gil Schwartzberg Owned Company Information

Luxte Biotech Holdings Inc

What is the work of Skechers USA Inc?

The Skechers GO brand is owned by the lifestyle footwear firm Skechers USA Inc. Women's shoes, men's shoes, kids' shoes, boys' shoes, work shoes, and performance shoes are among the products available. Accessories like clothing, purses, eyewear, toys, and many more are available. Its goods can be purchased from department and specialty stores, boutiques, independent athletic and other retailers, and online merchants. National wholesale, global wholesale, and direct-to-consumer are the company's operating divisions. The category that brings in the most money is international wholesale.

Who are Skechers USA Inc.'s top executives?

Owner number 10 percent of Skechers USA Inc. is Gil Schwartzberg. Other important leaders at Skechers USA Inc. comprise director & chief operating officer David Weinberg, chief marketing manager Leonard Armato, and chief financial officer John M Vandemore.

Insider Trading Activity for Skechers USA Inc.

Gil Schwartzberg has not engaged in any insider trading in Skechers USA Inc. over the past 18 months (SKX). Other significant insider sales featuring Skechers USA Inc (SKX) have included a net sell by Jeffrey Greenberg of 59,000 units, a net selling by Katherine J. Blair of 3,500 stocks, and a net export by Phillip Paccione of 1,302 shareholdings.

In conclusion, insiders traded 2,061 units of Skechers USA Inc (SKX) over the course of the last three months while also purchasing 0 shares, for a net selling of 2,061 shares. Insiders at Skechers USA Inc (SKX) sold 82,000 shares over the previous 18 months while buying 103,000 shares, for a net acquisition of 21,000 shares.

Lixte Biotech Holdings Inc

What is Lixte Biotech Holdings Inc responsible for?

Lixte Biotech Holdings Inc. is a drug discovery firm that develops innovative drugs to target enzymatic targets found in critical common diseases using biomarker technologies. The company's primary goal is to create novel therapeutics for human cancers, where these treatments are desperately required. It primarily creates medications that may be safely administered to patients and for which there is evidence of any effect on changed cancer cell pathways. Drugs for the treatment of cancer, such as protein phosphatase blockers and histone deacetylase inhibitors, are part of the company's development programme.

Who are Lixte Biotech Holdings Inc.'s top executives?

The 10% shareholder of Lixte Biotech Holdings Inc. is Gil Schwartzberg. Other important individuals of Lixte Biotech Holdings Inc. comprise Chief Medical Officer James Miser, Vice President and CFO Robert N Weingarten, and 10% owner Glenn Krinsky.

Lixte Biotech Holdings Inc (LIXT) Insider Trades Summary

Gil Schwartzberg has not engaged in any insider trading in Lixte Biotech Holdings Inc. from over past 18 months (LIXT). A net buy of 77,500 shares was made by Rene Bernards, a net acquisition of 41,112 shares was made by Eric Forman, and a net procurement of 5,000 units was made by Regina Brown, among other notable insider deals involving Lixte Biotech Holdings Inc (LIXT).

In conclusion, insiders acquired 123,612 shares of Lixte Biotech Holdings Inc (LIXT) during the past three months and sold 0 shares overall, for a net buy of 123,612 shares. Insiders of Lixte Biotech Holdings Inc (LIXT) purchased a net of 123,612 shares over the course of the previous 18 months after selling 0 shares during that time.

Spiking Race to 100

We are extremely excited to announce we have a new product called Race to 100. You can track the best investors who have made more than 100% profit in a year and replicate their portfolios in just a few clicks. Be the first to learn these top investors' new trades and trade alongside the shoulders of the giants. Try Race to hundred now at!

Join the Spiking Wealth Community

Want to learn more about the various trading strategies and see which one suits you the best? Led by Dr. Clemen Chiang, the Spiking Wealth Community is an online community network. Together we are catching the Spikes so that you have faith, hope, and love in everything you do. Spiking Wealth Community helps you to accomplish time squeeze by connecting the dots through online courses, live trading, winning trades, and more. Join us for Free and start your Spiking Wealth Journey today!

*Disclaimer: The article should not be taken as, and is not intended to provide investment advice. Claims made in this article do not constitute investment advice and should not be taken as such. Spiking strongly recommends that you perform your own independent research before making financial decisions